Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Chris Boylan who wrote (9001)	3/8/1999 5:39:00 PM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

You said>>>>>>>>>>>>>>Wrong. If they have as an end-point reduced morbidity, they need a certain number of people to die in order to have statistically valid results if they are going to go before the FDA AC and make an efficacy claim with regard to morbidity.<<<<< You don't need any kids to die to prove up reduced morbidity. One of the goals of this trial was to wait until a certain mortality figure was reached cumulative of both placebo and treated groups. It might interest you to know that historically speaking, administering Neuprex in Meningo. INCREASES morbidity. Hard to see how you can be long using your posts as a guide. It looks as though you just jumped in with some off the cuff ramblings.

To: Chris Boylan who wrote (9001)	3/8/1999 7:29:00 PM
From: xomadog2	Read Replies (3) \| Respond to of 17367

I believe that you are missing the point.The primary endpoint of this trial is mortality,not morbidity. Unless we agree on this fact there is no point in continuing the discussion we seem to be having. Yes, morbidity is a secondary endpoint.....and on that score I believe XOMA needs to have events other than mortality...morbid events...death is a morbid event but that is the primary endpoint.....multiplicity of morbid events (non death) are being measured for secondary endpoints. I hope this has enlarge the scope of your understanding of my point of view and that you are more in agreement with what I have said from reading this post.